+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antibody Drug Conjugate Market by Payload Type, Indication, Stage Of Development, Linker Type, Antibody Type, Conjugation Technology - Global Forecast to 2030- Product Image
Antibody Drug Conjugate Market by Payload Type, Indication, Stage Of Development, Linker Type, Antibody Type, Conjugation Technology - Global Forecast to 2030- Product Image
Sale

Antibody Drug Conjugate Market by Payload Type, Indication, Stage Of Development, Linker Type, Antibody Type, Conjugation Technology - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5896370
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Antibody Drug Conjugate (ADC) market is experiencing transformative growth, setting new standards for targeted therapeutics as biopharmaceutical innovations accelerate and companies seek advanced solutions for precision medicine. Senior executives navigating this space must address evolving trends, regulatory dynamics, and heightened competition to drive sustainable advantage.

Market Snapshot: Antibody Drug Conjugate Market

Driven by scientific breakthroughs and clinical progress, the ADC market grew from USD 6.48 billion in 2024 to USD 7.55 billion in 2025, and is forecast to maintain robust momentum with a CAGR of 16.24% through 2030. Projected to reach USD 15.99 billion by the end of the forecast period, the market’s trajectory underscores heightened demand for innovative targeted oncology therapies and diversification beyond traditional indications.

Scope & Segmentation

This research provides a granular assessment of the Antibody Drug Conjugate market, focusing on the full spectrum of value drivers, product innovations, and regional dynamics. The study analyzes the industry across the following core segments:

  • Payload Type: Auristatins (including MMAE, MMAF); Calicheamicins (notably N Acetyl Gamma Calicheamicin); Maytansinoids (DM1, DM4)
  • Indication: Breast Cancer (Her2 Positive, Triple Negative), Hematological Cancer (Leukemia, Lymphoma, Myeloma), Lung Cancer
  • Stage of Development: Approved, Phase I, Phase II, Phase III, Preclinical
  • Linker Type: Cleavable (Acid Cleavable, Disulfide Cleavable, Protease Cleavable), Non Cleavable (Thioether)
  • Antibody Type: Chimeric, Human, Humanized, Murine
  • Conjugation Technology: Conventional Conjugation, Site Specific Conjugation (Enzyme Based, Glycoengineering)
  • Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, and emerging EMEA markets), Asia-Pacific (China, India, Japan, Australia, South Korea, Southeast Asia)
  • Companies Profiled: Roche Holding AG, Seagen Inc., Daiichi Sankyo Company Limited, Pfizer Inc., AstraZeneca plc, ImmunoGen Inc., AbbVie Inc., Amgen Inc., GlaxoSmithKline plc, Astellas Pharma Inc.

Key Takeaways for Decision-Makers

  • Innovative payload formulations and advanced linker methods are redefining the standard of targeted drug delivery in oncology and select non-oncology domains.
  • Second- and third-generation ADCs leverage refined site-specific conjugation to optimize efficacy while minimizing toxicity, enabling new approaches in clinical development and trial design.
  • Bispecific antibodies and fully human scaffolds are reducing immunogenicity, expanding the pool of possible indications, and promoting adaptive, biomarker-driven patient selection.
  • Collaborative partnerships and strategic acquisitions among major pharmaceutical and biotech firms are accelerating development timelines, diversifying product portfolios, and enabling rapid scale-up of manufacturing infrastructure.
  • Regional differentiation in approval pathways, reimbursement models, and clinical infrastructure is shaping market entry strategies, with North America and Asia-Pacific notable for contrasting priorities in regulatory speed and cost-effective production.

Tariff Impact: Navigating New Regulatory Realities

The introduction of new US tariffs in 2025 is leading companies to reassess supply chains for key ADC components, including specialized linkers and antibodies. These changes are prompting contract renegotiations, increased exploration of regional sourcing alternatives, and consideration of domestic technology transfers. Cost pressures are influencing partner negotiations and trial planning, further emphasizing the need for flexible procurement and local manufacturing strategies to safeguard program viability.

Methodology & Data Sources

The report employs a robust methodology integrating primary interviews with leading industry figures alongside secondary research covering peer-reviewed publications, regulatory databases, and company disclosures. Quantitative and qualitative insights have been validated through triangulation and thematic coding to ensure data integrity and comprehensive coverage.

Why This Report Matters

  • Enables informed investment and portfolio expansion decisions by mapping current and emerging ADC technology opportunities.
  • Prepares organizations for evolving regulatory and cost environments, particularly in response to shifting tariffs and global supply chain dynamics.
  • Supports competitive positioning with actionable insights on market segmentation, regional dynamics, and the strategies of leading ADC developers.

Conclusion

As the ADC market matures and innovation accelerates, informed strategy and operational resilience will be essential for sustainable growth. This analysis equips executive teams to anticipate industry shifts, mitigate risk, and capture new opportunities in the advancing landscape of antibody drug conjugates.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antibody Drug Conjugate Market, by Payload Type
8.1. Introduction
8.2. Auristatins
8.2.1. Mmae
8.2.2. Mmaf
8.3. Calicheamicins
8.3.1. N Acetyl Gamma Calicheamicin
8.4. Maytansinoids
8.4.1. Dm1
8.4.2. Dm4
9. Antibody Drug Conjugate Market, by Indication
9.1. Introduction
9.2. Breast Cancer
9.2.1. Her2 Positive
9.2.2. Triple Negative
9.3. Hematological Cancer
9.3.1. Leukemia
9.3.2. Lymphoma
9.3.3. Myeloma
9.4. Lung Cancer
10. Antibody Drug Conjugate Market, by Stage Of Development
10.1. Introduction
10.2. Approved
10.3. Phase I
10.4. Phase Ii
10.5. Phase Iii
10.6. Preclinical
11. Antibody Drug Conjugate Market, by Linker Type
11.1. Introduction
11.2. Cleavable
11.2.1. Acid Cleavable
11.2.2. Disulfide Cleavable
11.2.3. Protease Cleavable
11.3. Non Cleavable
11.3.1. Thioether
12. Antibody Drug Conjugate Market, by Antibody Type
12.1. Introduction
12.2. Chimeric
12.3. Human
12.4. Humanized
12.5. Murine
13. Antibody Drug Conjugate Market, by Conjugation Technology
13.1. Introduction
13.2. Conventional Conjugation
13.3. Site Specific Conjugation
13.3.1. Enzyme Based
13.3.2. Glycoengineering
14. Americas Antibody Drug Conjugate Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Antibody Drug Conjugate Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Antibody Drug Conjugate Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Roche Holding AG
17.3.2. Seagen Inc.
17.3.3. Daiichi Sankyo Company, Limited
17.3.4. Pfizer Inc.
17.3.5. AstraZeneca plc
17.3.6. ImmunoGen, Inc.
17.3.7. AbbVie Inc.
17.3.8. Amgen Inc.
17.3.9. GlaxoSmithKline plc
17.3.10. Astellas Pharma Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ANTIBODY DRUG CONJUGATE MARKET MULTI-CURRENCY
FIGURE 2. ANTIBODY DRUG CONJUGATE MARKET MULTI-LANGUAGE
FIGURE 3. ANTIBODY DRUG CONJUGATE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ANTIBODY DRUG CONJUGATE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. ANTIBODY DRUG CONJUGATE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTIBODY DRUG CONJUGATE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MMAE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MMAF, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY N ACETYL GAMMA CALICHEAMICIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DM1, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DM4, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HER2 POSITIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPROVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACID CLEAVABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DISULFIDE CLEAVABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PROTEASE CLEAVABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY THIOETHER, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MURINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONVENTIONAL CONJUGATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ENZYME BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY GLYCOENGINEERING, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 85. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2030 (USD MILLION)
TABLE 86. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2030 (USD MILLION)
TABLE 87. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2030 (USD MILLION)
TABLE 88. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2030 (USD MILLION)
TABLE 89. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 90. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 91. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 92. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 93. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2030 (USD MILLION)
TABLE 94. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 95. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 96. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 97. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 98. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2030 (USD MILLION)
TABLE 99. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2030 (USD MILLION)
TABLE 100. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2030 (USD MILLION)
TABLE 101. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2030 (USD MILLION)
TABLE 102. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2030 (USD MILLION)
TABLE 103. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 105. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 106. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 107. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2030 (USD MILLION)
TABLE 108. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 109. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 110. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 111. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 112. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2030 (USD MILLION)
TABLE 170. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2030 (USD MILLION)
TABLE 171. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2030 (USD MILLION)
TABLE 172. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2030 (USD MILLION)
TABLE 173. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2030 (USD MILLION)
TABLE 174. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 175. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 176. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 177. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 178. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2030 (USD MILLION)
TABLE 179. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 180. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 181. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 182. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 183. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2030 (USD MILLION)
TABLE 184. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2030 (USD MILLION)
TABLE 185. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2030 (USD MILLION)
TABLE 186. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2030 (USD MILLION)
TABLE 187. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2030 (USD MILLION)
TABLE 188. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 189. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 190. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 191. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 192. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2030 (USD MILLION)
TABLE 193. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 194. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 195. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 196. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 197. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 206. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2030 (USD MILLION)
TABLE 207. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 208. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 209. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 210. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 211. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2030 (USD MILLION)
TABLE 212. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2030 (USD MILLION)
TABLE 213. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2030 (USD MILLION)
TABLE 214. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2030 (USD MILLION)
TABLE 215. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2030 (USD MILLION)
TABLE 216. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 217. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 218. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 219. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 220. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2030 (USD MILLION)
TABLE 221. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 222. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 223. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 224. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 225. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2030 (USD MILLION)
TABLE 226. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2030 (USD MILLION)
TABLE 227. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2030 (USD MILLION)
TABLE 228. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2030 (USD MILLION)
TABLE 229. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2030 (USD MILLION)
TABLE 230. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 231. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 232. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 233. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 234. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2030 (USD MILLION)
TABLE 235. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 236. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 237. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 238. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 239. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2030 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2030 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2030 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2030 (USD MILLION)
TABLE 254. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2030 (USD MILLION)
TABLE 256. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2030 (USD MILLION)
TABLE 258. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 260. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 262. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 264. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 266. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2030 (USD MILLION)
TABLE 268. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2030 (USD MILLION)
TABLE 270. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2030 (USD MILLION)
TABLE 272. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 274. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 280. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2030 (USD MILLION)
TABLE 282. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2030 (USD MILLION)
TABLE 283. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2030 (USD MILLION)
TABLE 284. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2030 (USD MILLION)
TABLE 285. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2030 (USD MILLION)
TABLE 286. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 287. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 288. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 289. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 290. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2030 (USD MILLION)
TABLE 291. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 292. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 293. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 294. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 295. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2030 (USD MILLION)
TABLE 296. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2030 (USD MILLION)
TABLE 297. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2030 (USD MILLION)
TABLE 298. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2030 (USD MILLION)
TABLE 299. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2030 (USD MILLION)
TABLE 300. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 301. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 302. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 303. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 304. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2030 (USD MILLION)
TABLE 305. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 306. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 307. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 308. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 309. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2030 (USD MILLION)
TABLE 310. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2030 (USD MILLION)
TABLE 311. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2030 (USD MILLION)
TABLE 312. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2030 (USD MILLION)
TABLE 313. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2030 (USD MILLION)
TABLE 314. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 315. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 316. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 317. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 318. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2030 (USD MILLION)
TABLE 319. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 320. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2030 (USD MILLION)
TABLE 321. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 322. QATAR ANTIBO

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Antibody Drug Conjugate market report include:
  • Roche Holding AG
  • Seagen Inc.
  • Daiichi Sankyo Company, Limited
  • Pfizer Inc.
  • AstraZeneca plc
  • ImmunoGen, Inc.
  • AbbVie Inc.
  • Amgen Inc.
  • GlaxoSmithKline plc
  • Astellas Pharma Inc.

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 7.55 Billion
Forecasted Market Value ( USD ) by 2030 $ 15.99 Billion
Compound Annual Growth Rate16.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antibody Drug Conjugates Contract Manufacturing Market by Product Type, Linker Type, Payload Chemistry, Development Stage, Service Type, Format Type, Conjugation Chemistry, Therapeutic Area, End-User - Global Forecast to 2030 - Product Image

Antibody Drug Conjugates Contract Manufacturing Market by Product Type, Linker Type, Payload Chemistry, Development Stage, Service Type, Format Type, Conjugation Chemistry, Therapeutic Area, End-User - Global Forecast to 2030

  • Report
  • 198 Pages
  • Global
From
Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key Geographical Regions - Product Image

Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key Geographical Regions

  • Report
  • 716 Pages
  • Global
From
Global Antibody Drug Conjugates Market - 2025-2035: Focus on Product, Application, Target, Payload Type, Linker Type, Linker Technology, and Geography - Product Image

Global Antibody Drug Conjugates Market - 2025-2035: Focus on Product, Application, Target, Payload Type, Linker Type, Linker Technology, and Geography

  • Report
  • Global
From
Antibody Drug Conjugates Contract Manufacturing - Global Strategic Business Report - Product Image

Antibody Drug Conjugates Contract Manufacturing - Global Strategic Business Report

  • Report
  • 168 Pages
  • Global
From
Antibody Drug Conjugate - Competitive Landscape, 2025 - Product Image

Antibody Drug Conjugate - Competitive Landscape, 2025

  • Report
  • 450 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.